Genmab A/S (GNMSF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 3,121,270 | 2,392,025 | 2,066,652 | 1,349,486 | 1,549,005 |
| Cost of Goods | 142,825 | 32,815 | N/A | N/A | N/A |
| Gross Profit | 2,978,445 | 2,359,210 | 2,066,652 | 1,349,486 | 1,549,005 |
| Operating Expenses | 2,007,335 | 1,587,416 | 1,166,501 | 869,322 | 581,854 |
| Operating Income | 971,935 | 772,609 | 900,151 | 480,164 | 967,152 |
| Interest Expense | 286,665 | 136,778 | 96,288 | 111,688 | 238,686 |
| Other Income | 643,510 | 182,662 | 192,293 | 265,220 | 176,027 |
| Pre-tax Income | 1,328,780 | 818,492 | 996,156 | 633,695 | 904,493 |
| Income Tax | 191,400 | 186,582 | 214,241 | 155,123 | 175,567 |
| Net Income Continuous | 1,137,380 | 631,910 | 781,915 | 478,573 | 728,926 |
| Net Income | $1,137,380 | $631,910 | $781,915 | $478,573 | $728,926 |
| EPS Basic Total Ops | 17.72 | 9.68 | 11.96 | 7.32 | 11.18 |
| EPS Basic Continuous Ops | 17.72 | 9.68 | 11.96 | 7.32 | 11.18 |
| EPS Diluted Total Ops | 17.60 | 9.59 | 11.84 | 7.25 | 11.06 |
| EPS Diluted Continuous Ops | 17.60 | 9.59 | 11.85 | 7.25 | 11.06 |
| EPS Diluted Before Non-Recurring Items | 14.60 | 11.80 | 11.85 | 7.24 | 11.18 |
| EBITDA(a) | $1,031,820 | $815,443 | $951,411 | $519,621 | $1,006,830 |